Informex news - Roche Colorado expands contract manufacturing of peptides

Roche Colorado, a leader in the large-scale manufacture of peptide APIs, is opening up its capabilities to provide a contract manufacturing service.

It is offering customers a complete package of services for APIs, including technical research and development, piloting, small-scale to multi-ton scale solid and solution phase peptide synthesis and purification, and proven regulatory expertise.

The company demonstrated its scale capability with Fuzeon, an anti-HIV drug licensed from Trimeris. The active ingredient in Fuzeon is a 36 amino acid peptide considered to be the most complex drug ever chemically synthesized at the multi-ton scale.

'Our goal is to apply our capabilities in pharmaceutical development and manufacturing to the compounds of other innovative companies,' said Dr Georg Wiebecke, president, Roche Colorado.

'With Fuzeon we have developed new ways to manufacture peptides in large scale, and our continuing technical progress has expanded our capacity. We now offer state-of-the-art technology, an effective, efficient infrastructure, and a passion for excellence at every phase of the manufacturing process.'